Xanthelasma: Heart Risk, Cholesterol, Weight Loss and Removal

Xanthelasma, the flat yellow plaques at the inner corners of the eyelids, are cholesterol deposits in the skin, and they matter more as a heart-risk signal than as a cosmetic problem. Only about half of the people who have them have high cholesterol.^[6] In the largest follow-up study, Danes with xanthelasma had 1.48 times the heart attack risk of those without, even after accounting for their cholesterol and triglycerides.^[1] Whether weight loss, or Ozempic, Wegovy, Mounjaro or Zepbound, makes the plaques shrink has never been studied. Lowering cholesterol occasionally does, in case reports. The plaques themselves rarely go away without removal, and they often come back afterward.

What xanthelasma is

Xanthelasma palpebrarum is the commonest form of xanthoma, a skin deposit of fat-laden immune cells. It shows up as soft, yellow, flat or slightly raised patches, usually on the upper lid near the nose, often on both sides. Estimates of how common it is vary with the population: about 1.1% of women and 0.3% of men in one review,^[20] 0.6% of adults attending an Israeli screening clinic,^[3] and 4.4% of a Danish general-population cohort that included many older people.^[1]

The plaques are not painful and do not affect vision. The American Academy of Ophthalmology notes that they do not go away on their own and tend to stay the same size or grow.^[11] They can be diagnosed by eye; a biopsy is only needed when the appearance is unusual.

Do they mean high cholesterol?

Often, but not reliably. A 1994 review found that, on average, only half of patients are hyperlipidemic,^[6] and the ophthalmology academy’s patient guidance gives the same split.^[11] Individual studies land all over the range:

Pooled across case-control studies, people with xanthelasma had higher LDL cholesterol and apolipoprotein B, and thicker carotid artery walls on ultrasound.^[5] The US Lipid Research Clinics surveys found the link strongest in young men.^[7] But a dermatology clinic in Nepal found dyslipidemia in 80% of patients,^[8] while a matched study in Iran^[9] and a large Israeli screening study found no more high cholesterol than in controls.^[3] The practical conclusion is the same either way: a normal cholesterol result does not explain the plaques away, and a first appearance at a young age is a stronger reason to check for an inherited lipid disorder.

The heart-risk evidence

In 1976–78 the Copenhagen City Heart Study enrolled 12,745 adults with no heart disease, recorded which of them had xanthelasma, and tracked the whole group for up to 33 years with complete follow-up.^[1] After adjusting for age, sex, total cholesterol, triglycerides, body mass index, blood pressure, diabetes, smoking and other factors, xanthelasma was linked to:

• 48% higher risk of heart attack (hazard ratio 1.48, 95% CI 1.23 to 1.79).
• 39% higher risk of ischemic heart disease (1.39, 1.20 to 1.60).
• 14% higher risk of death from any cause (1.14, 1.04 to 1.26).
• No higher risk of ischemic stroke (0.94, 0.73 to 1.21).

The extra risk was about the same in people whose cholesterol and triglycerides were below the cohort median as in those above it, which is why the study is cited as showing that the plaques signal risk independent of blood lipids.^[1] In absolute terms, men aged 70 to 79 with xanthelasma had a 53% ten-year risk of ischemic heart disease, against 41% without. For women of the same age it was 35% against 27%.^[1] A later analysis of the same cohort placed xanthelasma alongside male-pattern baldness and earlobe creases as visible signs that each added to heart risk.^[2]

The study has two limits. Nobody was taking a statin at baseline, because statins were not in general use in Denmark until 1994. LDL cholesterol was not measured at the start, so the adjustment used total cholesterol.^[1] The finding is also not unanimous:

• Israel, 2025. Among 35,452 adults at a screening institute, the 203 with xanthelasma had cardiovascular disease no more often than matched controls (8.9% vs 10%), with similar lipids and similar statin use.^[3] The study looked back at records and did not follow people forward for events.
• United States, 2026. In health records for 20,048 people with xanthelasma and as many matched controls, xanthelasma was linked to 26% more major cardiovascular events (hazard ratio 1.26) and 38% more new hyperlipidemia diagnoses.^[4] Record-based diagnoses are less precise than a research examination.

The weight of the evidence supports treating xanthelasma as a prompt for a heart-risk check: a lipid panel, blood pressure, blood sugar and smoking history, read together. It does not mean a heart attack is coming. For how a statin fits with a GLP‑1 if one is prescribed, see statins and a GLP-1.

Is weight a cause?

Less clearly than people assume. The ophthalmology academy lists being overweight among risk factors.^[11] The data are mixed. The US Lipid Research Clinics surveys found no consistent link between xanthelasma and obesity,^[7] and a 2022 case-control study in India found people with xanthelasma were less likely than matched controls to be overweight or obese (odds ratio 0.2).^[10] The Copenhagen risk estimates were already adjusted for body mass index.^[1] Xanthelasma is common in people of normal weight, and there is no evidence that weight is what drives it.

Will losing weight or a GLP-1 make them fade?

No study has tested it. Nothing has been published, not even a case report, on xanthelasma changing after diet-driven weight loss, bariatric surgery, or semaglutide, liraglutide or tirzepatide treatment. Any claim that Ozempic or Mounjaro clears eyelid plaques has nothing published behind it.

What the drugs do to blood lipids is on their labels, and it is modest for LDL, the cholesterol most tied to these deposits. In the main Wegovy weight trial, LDL fell 3.8% more than on placebo and triglycerides 15.8% more.^[12] In SELECT, the Wegovy heart trial, LDL fell 2.2% more than on placebo.^[12] Zepbound lowered LDL 2.9% to 5.5% more than placebo across its doses, triglycerides 16.5% to 24.9%, and raised HDL about 8% to 10%.^[13] The lowest dose of Lipitor, by comparison, cut LDL by 39% in its dose-response trials, and the highest by 60%.^[14] The labels note the GLP‑1 lipid results were not part of the trials’ formal testing. A side-by-side table is in statins and a GLP-1, and the wider list of non-weight changes is in what else GLP-1 drugs change.

So on lipid grounds alone, a GLP‑1 is a weak candidate for shrinking xanthelasma. Its heart benefit in SELECT came with very little change in LDL, which says the drug protects through other routes; it does not say the eyelid plaques will respond.

Do cholesterol drugs shrink them?

Sometimes, mostly in case reports, and only after large or sustained drops in LDL. The evidence, in full:

• The only comparative series. Over 12 months in Japan, plaques regressed in 13 of 36 patients on probucol and in 1 of 18 on pravastatin, a statin.^[15] Probucol is not sold in the United States.
• Single cases on statins. One report described plaques disappearing after simvastatin,^[16] and another described regression on a statin in a patient whose cholesterol was normal to begin with.^[17]
• A single case on a PCSK9 drug. A man with familial hypercholesterolemia kept large plaques through years of statin and ezetimibe treatment; they disappeared after 26 months of alirocumab (Praluent) as his LDL fell from 164 to 47 mg/dL. The authors noted that statins and other lipid drugs do not usually change xanthelasma.^[18]

Case reports are published because they are unusual, so they say nothing about how often it happens. One review sums up the role of medicine as limited.^[20] The reason to treat high cholesterol in someone with xanthelasma is the heart, not the eyelids.

Removal: what works and how often it comes back

Removal is the only reliable way to get rid of the plaques, and it is cosmetic. Most of the evidence is weak: a 2023 systematic review of 49 studies covering 1,329 patients found 69% were retrospective and 84% had no comparison group.^[21]

The first head-to-head randomized trial, published in 2026, treated one eye of each patient with surgical excision and the other with 70% trichloroacetic acid. All 36 excised sites cleared completely at 12 weeks, against 8 of 36 treated with acid, and color changes were more common after acid (75% against 42%).^[23] The trial only included small lesions and followed patients for 12 weeks, too short to measure recurrence. Laser figures come from the 2023 review^[21] and an earlier review of 21 laser studies, which found moderate to excellent clearance across laser types.^[22]

Recurrence is the long-term problem. In a 1976 surgical series, excision was permanent for more than half of first-time patients, and recurrence was to be expected when all four eyelids were involved, when an underlying lipid disorder was present, or after more than one previous recurrence.^[19] A later review cites that series as reporting recurrence in 40% after a first excision, 60% after a second, and 80% when all four lids were affected.^[20] In the 2023 review, three of the four patients with recurrence in two surgical studies had uncontrolled high cholesterol.^[21] The ophthalmology academy suggests managing cholesterol may help keep plaques from returning.^[11] That is plausible, but no trial has tested it.

What to ask a clinician

1. Can I have a full lipid panel? Include LDL, HDL, triglycerides and, if available, apolipoprotein B or lipoprotein(a), especially if the plaques appeared before 40.
2. What is my ten-year heart risk? Xanthelasma is not part of the standard calculators, so ask whether it changes how your result is read.
3. Do I need a statin? That decision rests on LDL and overall risk. A GLP‑1 does not substitute for one on LDL.
4. Should I check my thyroid, blood sugar or liver? These can raise lipids and are worth ruling out.
5. Which removal method suits the size and depth of my plaques? Ask about scarring, color change, and what happens if they come back.